DNA demethylating agent 5-azacytidine inhibits myeloid-derived suppressor cells induced by tumor growth and cyclophosphamide treatment

Journal of Leukocyte Biology

Volumn 95, Issue 5, 2014, Pages 743-753

  Mikyšková, Romana ^a   Indrová, Marie ^a   Vlková, Veronika ^a   Bieblová, Jana ^a   Šímová, Jana ^a   Paračková, Zuzana ^a   Pajtasz Piasecka, Elzbieta ^b   Rossowska, Joanna ^b   Reiniš, Milan ^a  

^a INSTITUTE OF MATHEMATICS   (Czech Republic)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Arginase 1; Immunosuppression; Microenvironment

Indexed keywords

AZACITIDINE; CYCLOPHOSPHAMIDE; PROTEIN; PROTEIN ARG 1; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL SUSPENSION; COMPARATIVE STUDY; CONTROLLED STUDY; DNA METHYLATION; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; IN VITRO STUDY; LYMPHOCYTE SUBPOPULATION; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; SPLEEN; SUPPRESSOR CELL; TUMOR GROWTH; ANIMAL; IMMUNOLOGY; MYELOID-DERIVED SUPPRESSOR CELL; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; MALE; MICE; MYELOID-DERIVED SUPPRESSOR CELLS; NEOPLASMS, EXPERIMENTAL;

EID: 84899804950     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.0813435     Document Type: Article

References (44)

1. Gabrilovich, D. I., Ostrand-Rosenberg, S., Bronte, V. (2012) Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 22, 253-268.
2. Gabrilovich, D. I., Nagaraj, S. (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174.
3. Umansky, V., Sevko, A. (2012) Tumor microenvironment and myeloidderived suppressor cells. Cancer Microenvironment 61, 275-282.
4. Sevko, A., Umansky, V. (2013) Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. J. Cancer 4, 3-11.
5. Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P., Van Ginderachter, J. A. (2008) Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111, 4233-4244.
6. Youn, J. I., Nagaraj, S., Collazo, M., Gabrilovich, D. I. (2008) Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181, 5791-5802.
7. Kusmartsev, S., Gabrilovich, D. I. (2003) Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J. Leukoc. Biol. 74, 186-196.
8. Kusmartsev, S., Gabrilovich, D. I. (2006) Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol. Immunother. 55, 237-245.
9. Rodriguez, P. C., Quiceno, D. G., Ochoa, A. C. (2007) L-Arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109, 1568-1573.
10. Zea, A. H., Rodriguez, P. C., Atkins, M. B., Hernandez, C., Signoretti, S., Zabalet, J., McDermott, D., Quiceno, D., Youmans, A., O'Neill, A., Mier, J., Ochoa, A.C. (2005) Arginase producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65, 3044-3048.
11. Rodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., Antonia, S., Ochoa, J. B., Ochoa, A. C. (2004) Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64, 5839-5849.
12. Bronte, V., Apolloni, E., Cabrelle, A., Ronca, R., Serafini, P., Zamboni, P., Restifo, N. P., Zanovello, P. (2000) Identification of a CD11b+/Gr-1β/CD31β myeloid progenitor capable of activating or suppressing CD8+ T cells. Blood 96, 3838-3846.
13. Serafini, P., De Santo, C., Marigo, I., Cingarlini, S., Dolcetti, L., Gallina, G., Zanovello, P., Bronte, V. (2004) Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 53, 64-72.
14. Angulo, I., de las Heras, F. G., García-Bustos, J. F., Gargallo, D., Muñoz-Fernández, M. A., Fresno, M. (2000) Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. Blood 95, 212-220.
15. Peláez, B., Campillo, J. A., López-Asenjo, J. A., Subiza, J. L. (2001) Cyclophosphamide induces the development of early myeloid cells suppressing tumor cell growth by a nitric oxide-dependent mechanism. Immunology 166, 6608-6615.
16. Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., Montero, A. J. (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58, 49-59.
17. Mikyšková, R., Indrová, M., Polláková, V., Bieblová, J., Šímová, J., Reiniš, M. (2012) Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumours. J. Immunotherapy 35, 376-384.
18. Emadi, A., Jones, R. J., Brodsky, R. A. (2009) Cyclophosphamide and cancer: golden anniversary. Nat. Rev. Clin. Oncol. 611, 638-647.
19. Ugel, S., Delpozzo, F., Desantis, G. (2009) Therapeutic targeting of myeloid-derived suppressor cells. Curr. Opin. Pharmacol. 9, 470-481.
20. Blum, W., Klisovic, R. B., Hackanson, B., Liu, Z., Liu, S., Devine, H., Vukosavljevic, T., Huynh, L., Lozanski, G., Kefauver, C., Plass, C., Devine, S. M., Heerema, N. A., Murgo, A., Chan, K. K., Grever, M. R., Byrd, J. C., Marcucci, G. (2007) Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J. Clin. Oncol. 25, 3884-3891.
21. Cashen, A. F., Schiller, G. J., O'Donnell, M. R., Dipersio, J. F. (2010) Multicenter phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J. Clin. Oncol. 28, 556-561.
22. Kantarjian, H, Issa, J. P., Rosenfeld, C. S., Bennett, J. M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F, Helmer III, R., Shen, L., Nimer, S. D., Leavitt, R., Raza, A., Saba, H. (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106, 1794-1803.
23. Tomasi, T. B., Magner, W. J., Khan, A. N. (2006) Epigenetic regulation of immune escape genes in cancer. Cancer Immunol. Immunother. 55, 1159-1184.
24. Manning, J., Indrová, M., Lubyová B, Přibylová, H., Bieblová, J., Hejnar, J., Šímová, J., Jandlová, T., Bubeník, J., Reiniš, M. (2008) Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours. Immunology 123, 218-227.
25. Šímová, J., Polláková, V., Indrová, M., Mikyšková, R., Bieblová, J., Štěpánek, I., Bubeník, J., Reiniš, M. (2011) Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status. Brit. J. Cancer 105, 1533-1541.
26. Setiadi, A. F., David, M. D., Seipp, R. P., Hartikainen, J. A., Gopaul, R., Jefferies, W. A. (2007) Epigenetic control of the immune escape mechanisms in malignant carcinomas. Mol. Cell. Biol. 27, 7886-7894.
27. Reiniš, M. (2010) Immunotherapy of MHC class I-deficient tumors. Future Oncol. 6, 1577-1589.
28. Štěpánek, I., Indrová, M., Bieblová, J., Fučiková, J., Spíšek, R., Bubeník, J., Reiniš, M. (2011) Effects of unmethylated CpG oligodeoxynucleotides, TNFα, and epigenetic agents on dendritic cell maturation. J. Biol. Regul. Homeost. Agents 25, 517-529.
29. Nencioni, A., Beck, J., Werth, D., Grünebach, F., Patrone, F., Ballestrero, A., Brossart, P. (2007) Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin. Cancer Res. 13, 3933-3941.
30. Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., Albelda, S. M. (2005) Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11, 6713-6721.
31. Ghiringhelli, F., Bruchard, M., Apetoh, L. (2013) Immune effects of 5-fluorouracil: ambivalence matters. Oncoimmunology 2, e23139.
32. Kodumudi, K. N., Woan, K., Gilvary, D. L., Sahakian, E., Wei, S., Djeu, J. Y. (2010) A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 16, 4583-4594.
33. Sevko, A., Michels, T., Vrohlings, M., Umansky, L., Beckhove, P., Kato, M., Shurin, G. V., Shurin, M. R., Umansky, V. (2013) Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J. Immunol. 190, 2464-2471.
34. Daurkin, I., Eruslanov, E., Vieweg, J., Kusmartsev, S. (2010) Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2=-deoxycytidine. Cancer Immunol. Immunother. 59, 697-706.
35. Triozzi, P. L., Aldrich, W., Achberger, S., Ponnazhagan, S., Alcazar. O., Saunthararajah, Y. (2012) Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice. Cancer Immunol. Immunother. 61, 1441-1450.
36. Rosborough, B. R., Castellaneta, A., Natarajan, S., Thomson, A. W., Turnquist. H. R. (2012) Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo. J. Leukoc. Biol. 91, 701-709.
37. Lin, K. Y., Guarnieri, F. G., Staveley-O'Carroll, K. F., Levitsky, H. I., August, J. T., Pardoll, D. M., Wu, T. C. (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56, 21-26.
38. Šmahel, M., Šíma, P., Ludvíková, V., Marinov, I., Pokorná D., Vonka, V. (2003) Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. Vaccine 21, 1125-1136.
39. Foster, B. A., Gingrich, J. R., Kwon, E. D., Madias, C., Greenberg, N. M. (1997) Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 57, 3325-3330.
40. Indrová, M., Bieblová, J., Bubeník, J., Reiniš, M. (2008) IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets. Int. J. Oncol. 32, 499-507.
41. Rossowska, J., Pajtasz-Piasecka, E., Ryoenik, O., Wojas, J., Krawczenko, A., Szyda, A., Duoe, D. (2011) Generation of antitumor response by IL-2-transduced JAWS II dendritic cells. Immunobiology 216, 1074-1084.
42. Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., Ghiringhelli, F. (2010) 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70, 3052-3061.
43. Michels, T., Shurin, G. V., Naiditch, H., Sevko, A., Umansky, V., Shurin, M. R. (2012) Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. J. Immunotoxicol. 9, 292-300.
44. Sánchez-Abarca, L. I., Gutierrez-Cosio, S., Santamaría, C., Caballero-Velazquez, T., Blanco, B., Herrero-Sánchez, C., García, J. L., Carrancio, S., Hernández-Campo, P., González, F. J., Flores, T., Ciudad, L., Ballestar, E., Del Cañizo, C., San Miguel, J. F., Pérez-Simon, J. A. (2010) Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood 115, 107-121.